Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.

Of note, in the QUEST study, in patients taking high‐dose ICS a significant reduction in the adjusted annualized severe exacerbation rate with dupilumab vs matched placebo was observed in the subgroup of patients with baseline eosinophils ≥300 μ/L; a similar trend was observed in the phase 2b study although the effect did not reach statistical significance, likely due to low patient numbers in the subgroups of the phase 2b study.

also in 111,027 other papers